VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

BACKGROUND: The serum proteomic test VeriStrat has been shown to be able to classify advanced non-small cell lung cancer (NSCLC) patients for overall survival (OS) after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). In this study, VeriStrat was evaluated a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kuiper, J L, Lind, J S W, Groen, H J M, Roder, J, Grigorieva, J, Roder, H, Dingemans, A M C, Smit, E F
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2012
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3505013/
https://ncbi.nlm.nih.gov/pubmed/23079575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.470
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars